Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
EntrestoⓇ delivers strong growth across all geographies
Sales evolution
USD m, % cc
Ex-US
US
US weekly TRX2
Total prescriptions (000)
100
+44%
90
1,291
80
70
949
597
429
40
30
694
20
520
10
0
Q4 2021
Q4 2022
July 2015
82220
60
50
Jan 2023
GROWTH
Entresto
Strong Q4 momentum across geographies
US: NBRX +16% vs PY, ~1.2m TRx in Q41
EU: continued growth in HFrEF
China/Japan: significant contribution from HTN²
FY sales 4.6bn (+37% cc, +1.1bn)
Confidence in future growth³
US/EU: further penetration in CHF
Strong clinical profile and RW data in heart failure
China/Japan: launch momentum in HTN
TRX - total prescriptions. HFrEF heart failure with reduced ejection fraction. CHF chronic heart failure. RW real world. HTN - hypertension. 1. IQVIA National Prescription Audit. 2. Approved indications differ by geography.
Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in patients with LVEF below normal." (US) HFrEF (EU) HFrEF and HTN (China and
JP). HTN is not an approved indication in the US. 3. For forecasting purposes, we assume EntrestoⓇ LOE in 2025.
23 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation